The effect of simvastatin on lymphocyte secretory function in patients with impaired fasting glucose

Journal of Cardiovascular Pharmacology

Volumn 56, Issue 5, 2010, Pages 491-497

  Krysiak, Robert ^a   Okopien, Boguslaw ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

(TNF ); impaired fasting glucose; interferon g; interleukin 2; isolated hypercholesterolemia; lymphocytes; statins; tumor necrosis factor

Indexed keywords

C REACTIVE PROTEIN; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; LIPID; PHYTOHEMAGGLUTININ; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; ATHEROSCLEROSIS; BEDTIME DOSAGE; CONTROLLED STUDY; CYTOKINE RELEASE; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; GLUCOSE TOLERANCE; HUMAN; HYPERCHOLESTEROLEMIA; IMPAIRED FASTING GLUCOSE; LIPID BLOOD LEVEL; LYMPHOCYTE; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

BLOOD GLUCOSE; DYSLIPIDEMIAS; FASTING; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INTERFERON-GAMMA; INTERLEUKIN-2; LIPIDS; LYMPHOCYTES; MALE; MIDDLE AGED; SIMVASTATIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78649388724     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181f301e0     Document Type: Article

References (32)

1. Twigg SM, Kamp MC, Davis TM, et al; Australian Diabetes Society; Australian Diabetes Educators Association. Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association. Med J Aust. 2007;186:461-465.
2. Petersen JL, McGuire DK. Impaired glucose tolerance and impaired fasting glucose\a review of diagnosis, clinical implications and management. Diab Vasc Dis Res. 2005;2:9-15.
3. Colhoun HM, Betteridge DJ, Durrington PN, et al; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364: 685-696.
4. Ridker PM, Danielson E, Fonseca FA, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
5. Athyros VG, Kakafika AI, Tziomalos K, et al. Pleiotropic effects of statins\clinical evidence. Curr Pharm Des. 2009;15:479-489.
6. Blum A, Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogene-sis. Atherosclerosis. 2009;203:325-330.
7. Krysiak R, Okopień B, Herman ZS. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs. 2003;63: 1821-1854.
8. Okopień B, Krysiak R, Kowalski J, et al. The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia. Atherosclerosis. 2004;176:327-335.
9. Yilmaz A, Reiss C, Weng A, et al. Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J Leukoc Biol. 2006;79:529-538.
10. Leung BP, Sattar N, Crilly A, et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol. 2003;170:1524-1530.
11. Neuhaus O, Strasser-Fuchs S, Fazekas F, et al. Statins as immunomo-dulators: comparison with interferon-beta 1b in MS. Neurology. 2002;59: 990-997.
12. Horimoto H, Nakai Y, Nakahara K, et al. HMG-CoA reductase inhibitor cerivastatin prolonged rat cardiac allograft survival by blocking intercellular signals. J Heart Lung Transplant. 2002;21:440-445.
13. Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6:1399-1402.
14. Kwak B, Mulhaupt F, Veillard N, et al. The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. Swiss Med Wkly. 2001;131:41-66.
15. Sadeghi MM, Tiglio A, Sadigh K, et al. Inhibition of interferon-gamma- mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors. Transplantation. 2001;71:1262-1268.
16. McCarey DW, McInnes IB, Madhok R, et al. Trial of atorvastatin in rheumatoid arthritis (TARA): double blind, placebo-controlled trial. Lancet. 2004;363: 2015-2021.
17. Kanda H, Yokota K, Kohno C, et al. Effects of low-dosage simvastatin on rheumatoid arthritis through reduction of Th1/Th2 and CD4/CD8 ratios. Mod Rheumatol. 2007;17:364-368.
18. Okamoto H, Koizumi K, Kamitsuji S, et al. Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort. J Rheumatol. 2007;34:964-968.
19. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006;86:515-581.
20. Schroecksnadel K, Frick B, Winkler C, et al. Crucial role of interferon-gamma and stimulated macrophages in cardiovascular disease. Curr Vasc Pharmacol. 2006;4:205-213.
21. Dembowski E, Davidson MH. A review of lipid management in primary and secondary prevention. J Cardiopulm Rehabil Prev. 2009;29:2-12
22. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360: 7-22.
23. Garg A, Simha V. Update on dyslipidemia. J Clin Endocrinol Metab. 2007;92:1581-1589.
24. Weyand CM, Younge BR, Goronzy JJ. T cells in arteritis and atherosclerosis. Curr Opin Lipidol. 2008;19:469-477.
25. Hansson GK. Inflammatory mechanisms in atherosclerosis. J Thromb Haemost. 2009;7(Suppl 1):328-331.
26. Ridker PM. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev. 2007;65:S253-S259.
27. Kinlay S, Egido J. Inflammatory biomarkers in stable atherosclerosis. Am J Cardiol. 2006;98:P2-P8.
28. Martin JH, Mangiafico S, Kelly DJ. Role of statins in diabetes complications. Curr Diabetes Rev. 2009;5:165-170.
29. Sabatine MS, Wiviott SD, Morrow DA, et al. High dose atorvastatin associated with worse glycemic control: a PROVE-IT TIMI 22 substudy. Circulation. 2004;110(Suppl):S834.
30. Yamakawa T, Takano T, Tanaka S, et al. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb. 2008;15:269-275.
31. Jasińska M, Owczarek J, Orszulak-Michalak D. Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol Rep. 2007;59:483-499.
32. Buhaescu I, Izzedine H. Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem. 2007;40:575-584.